CA-JSR-LIFE-SCIENCES
10.5.2022 14:02:15 CEST | Business Wire | Press release
JSR Life Sciences, LLC (JSR) today announced the launch of a new business division, Similis Bio (Similis), which will operate a partnering program designed to help biopharmaceutical companies improve the efficiency and cost of biosimilar development. Similis will rely on core expertise in developing and manufacturing biologics to mitigate the challenges inherent in biosimilar drug development.
Similis provides biosimilar drug developers with solutions designed to accelerate development timelines and lower costs. By offering complete analytical and process development packages, Similis supplies companies with data to determine an appropriate biosimilar target, accelerate early program development, and reduce analytical costs. Data packages include reference product data, analytical procedures, process expertise, and CMC templates from a centralized model designed to give partners access to higher quality biosimilar packages at a lower cost than other development models.
Additionally, Similis will establish co-development agreements with partner companies to start the development of multiple biosimilar programs in parallel, giving partners an exclusive right, but not an obligation, to purchase multiple programs. JSR designed this collaboration model to reduce the risk from program cancellations and extend market analysis timelines.
“This model will enable changes in strategy far beyond traditional drug development approaches by centralizing reference product data and expertise under one roof,” said JSR Life Sciences’ Chief Technology Officer Jean-Pierre Wery. “Similis brings the broad expertise of JSR Life Sciences companies together to jump-start the development of promising biosimilars. By improving timelines and development costs for drug makers, more biosimilars can be brought to market faster. Ultimately, that means more choice and lower costs for patients.”
Biosimilars—the generic form of FDA-approved biologics—are derived from living organisms, making them inherently complex. Unlike small-molecule generic drugs, biosimilars cannot fully replicate their brand-name counterparts, so an array of analytical data must be collected to ensure they sufficiently reflect biosimilarity to the FDA-approved reference products to which they are being compared. This process requires costly and significant investment in expertise, state-of-the-art technology, and extensive data gathering, including rigorous clinical trials to ensure a biosimilar's safety and efficacy. JSR launched Similis Bio to mitigate these barriers to market entry and promote more productive development programs.
For more information about Similis Bio visit: JSRLifeSciences.com/similis .
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay’s Pink Changing Lives® Program Turns Purpose Into Measurable Impact for Women Around the World6.8.2026 14:05:00 CEST | Press release
More than 4 million women have benefited through nonprofit organizations supported by the program since its launch. Mary Kay Inc., a global advocate for women’s empowerment, proudly reaffirms its commitment to enriching women’s lives worldwide through its signature Pink Changing Lives® Program – a multi-faceted global initiative that blends purpose-driven giving with cause-marketing to create meaningful, measurable impact across communities. Since 1996, the program has provided over $230 million in monetary and product donations to nonprofit organizations empowering women, transforming women’s health and safety, and protecting our natural resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806671194/en/ Mary Kay China supports the Hope for Pearl Program, providing financial assistance to girls from economically disadvantaged areas to receive a life-changing education, opening doors to new possibilities and bright fu
Perpetuals Reports 380% Hypothetical Return in Backtest of AI Engine Powering Risk-Free Trading Platform ‘UpsideOnly’6.8.2026 14:00:00 CEST | Press release
Results provide early evidence that BayesShield can identify potentially profitable trading signals by finding repeatable skill in trader activity375-day backtest using Perpetuals’s production code generated a hypothetical 380% non-compounded return, a period in which Bitcoin fell 40.2%The strategy achieved a return-to-drawdown ratio of 4.4, a measure comparing its overall return with the largest decline it experienced during the test Perpetuals.com Ltd (Nasdaq: PDC) today announced backtest results for version two of BayesShield, its patent-pending AI engine developed for UpsideOnly. UpsideOnly is a risk-free paper trading platform where users simulate trades using virtual money across global equity, commodity, foreign exchange and crypto markets. The platform is powered by BayesShield, an AI model that uses machine learning to identify consistently successful traders. It generates automated signals when enough qualified traders independently take the same position at approximately th
Adtran launches Mosaic One Fabric, empowering operators to build custom AI agents and workflows6.8.2026 14:00:00 CEST | Press release
News summary: Operators need the autonomy and tools to create AI agents and workflows that address their own business priorities Adtran’s Mosaic One Fabric enables operators to create, govern and scale AI agents without vendor lock-in Open foundation gives operators more control over their data, agents and token economics while accelerating innovation Adtran today launched Mosaic One Fabric, an expansion of its Mosaic One software platform, enabling operators to create AI agents and workflows around their own operational priorities. Rather than being limited to predefined agents, fixed use cases or vendor-controlled ecosystems, operators can build and scale AI on their own terms using the data, tokens and models that best fit their business, with the token economics visible and under their control. Mosaic One Fabric brings together trusted operational intelligence, vendor-agnostic AI integration and the guardrails needed to run AI safely across the network. By combining Adtran capabili
NetApp Acquires JetStream Software to Advance Cyber Resilience and Data Protection for the AI Era6.8.2026 14:00:00 CEST | Press release
Acquisition strengthens NetApp’s portfolio with recovery and mobility capabilities that help organizations reduce risk and accelerate transformation NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has acquired JetStream Software, a leader in VMware disaster recovery and migration. Enterprise customers continue to rely on VMware for many of their most critical applications. As organizations evaluate cloud adoption, they often seek ways to transition workloads while minimizing cost, complexity, and operational disruption. For many, disaster recovery serves as a practical first step, with production workloads migrating over time as cloud strategies mature. “Data has become the foundation for business growth, AI innovation, and operational continuity,” said George Kurian, Chief Executive Officer at NetApp. “As customers look to unlock greater value from their data while strengthening protection against disruption, bringing JetStream into NetApp expan
Omilia Secures $67 Million in Series B Funding to Accelerate Global Expansion of Its Agentic Self-Learning CX Platform for Large Enterprises6.8.2026 14:00:00 CEST | Press release
ARR surpasses $60 million, growth of more than 10x since the company's Series ANamed a Leader in The Forrester Wave™ Conversational AI Platforms for Customer Service, Q2 2026Investment led by transatlantic software & AI specialist Expedition Growth Capital Omilia, the Self-Learning Agentic CX company trusted by many of the world's largest enterprises, today announced a $67 million Series B funding round led by transatlantic software & AI specialist, Expedition Growth Capital. Omilia builds Agentic CX for the world's largest and most demanding enterprises – organizations often in regulated industries such as banking, insurance and healthcare, where security, scalability and cost predictability are non-negotiable. Its customers include Capital One, Discover, RBC, Taco Bell, DWP and PSEG. The company's voice-first AI platform, honed over more than 200 enterprise deployments, is built entirely on its own proprietary agentic Voice AI technology, and supports the most stringent enterprise se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom